Agios Announces Publication of Phase 3 ACTIVATE-T Data in

– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Regularly Transfused, PYRUKYND® Demonstrated a Statistically Significant and Clinically Meaningful...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Denmark ,Copenhagen ,Køavn ,Andreas Glenth ,Jessica Rennekamp ,Sarah Gheuens ,Holly Manning ,Pk Deficiency Foundation ,European Hematology Association ,Drug Administration ,Nasdaq ,Exchange Commission ,Corporate Communications ,European Medicines Agency ,Agios Pharmaceuticals Inc ,Department Of Hematology ,Pyruvate Kinase ,Deficiency Who Are Regularly Transfused ,Statistically Significant ,Clinically Meaningful Reduction ,Transfusion Burden ,Only Disease Modifying Treatment ,New England Journal ,Substrates Including Hormonal Contraceptives ,Prescribing Information ,Private Securities Litigation Reform Act ,Risk Factors ,Nasdaq Agio ,Agios Pharmaceuticals ,Nc ,